Liposidomycin C (C42H67N5O21 S, M.W. 1009) is a novel nucleoside antibiotic containing uracil, a sulfated aminosugar, and a fatty acid.It is a specific inhibitor of peptidoglycan synthesis of bacteria, inhibiting the formation of the lipid intermediates from uridine S'-diphospho-V-acetylmuramyl-ialanyl-D-glutamyl-/w^5<?-diaminopimelyI-D-[14C]alanyl-D-[1 4C]alanine and uridine 5'-diphospho-/Vacetylglucosamine with a particulate enzyme from Escherichia coli Y-10.It also inhibited the formation of MurNAc(-pentapeptide)-P-P-lipid in the absence of UDP-GlcNAc.On the other hand, it inhibited the activity of N-acetylglucosamine transglycosylase and peptidoglycan transglycosylase only weakly using the same system from E. coli.Thus, it is concluded that the site of action of liposidomycin C is phospho-/V-acetylmuramyl-pentapeptide transferase in peptidoglycan synthesis.
No takes yet. Share an insight, caveat, or question.
Kimura et al. (1989) studied this question.